SG11201806127XA - Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate - Google Patents

Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate

Info

Publication number
SG11201806127XA
SG11201806127XA SG11201806127XA SG11201806127XA SG11201806127XA SG 11201806127X A SG11201806127X A SG 11201806127XA SG 11201806127X A SG11201806127X A SG 11201806127XA SG 11201806127X A SG11201806127X A SG 11201806127XA SG 11201806127X A SG11201806127X A SG 11201806127XA
Authority
SG
Singapore
Prior art keywords
international
hmb
beta
pharmaceutical
pct
Prior art date
Application number
SG11201806127XA
Inventor
Shreeram Sathyavageeswaran
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SG11201806127XA publication Critical patent/SG11201806127XA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38Other non-alcoholic beverages
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11111111011110111010101111101011111011101110101111110111011001111101111011111 International Bureau ... .... ..Yjd ..... .„,,,, (10) International Publication Number (43) International Publication Date WO 2017/127333 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: (72) Inventor: SATHYAVAGEESWARAN, Shreeram; c/o A61K 31/12 (2006.01) A61P 3/04 (2006.01) Abbott Laboratories, 100 Abbott Park Road, Abbott Park, A61K 31/19 (2006.01) 60064-3500 (US). (21) International Application Number: (74) Agent: KOZLOWSKI, Holly; Porter Wright Morris & PCT/US2017/013672 Arthur LLP, 41 South High Street, Columbus, Ohio 43215 (US). (22) International Filing Date: 16 January 2017 (16.01.2017) (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (25) Filing Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 1600990.4 19 January 2016 (19.01.2016) GB KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (71) Applicant: ABBOTT LABORATORIES [US/US]; 100 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, Abbott Park Road, Abbott Park, Illinois 60064-3500 (US). NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, [Continued on next page] TYRATE - = 380 — = - 360 = (54) Title: PHARMACEUTICAL OR NUTRITIONAL COMBINATION COMPRISING BETA-HYDROXY-BETAMETHYLBU- (57) : The present invention relates to a pharmaceutical or nutri- Lean tional combination comprising beta-hydroxy beta-methylbutyrate (HMB) and tetrahydrocurcumin (THC) and methods comprising administering the combination to a subject. The methods of the invention relate to at- t tenuating muscle protein degradation and/or preserving lean body mass in 340 = = m 320 as = M 300 = _ the subject. * ** * T T 280 = 260 .;' ,,, 240 — Day 21 = = 7 333 Al I I I I 1111 1111 1111 1111111 II II Saline control Path Control HMB 160 HMB 320 White Curcumin 100 . , White Curcumin 200 HMB 160 + White Curcumin 100 i'l 1-1 IN FIG. 3 ,-, © ei O WO 2017/127333 Al MIDEDIMOMOIDEIRMEMOMOHMERMOOMOVOIMIE (84) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). kind of regional protection available): ARIPO (BW, GH, Published: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, — TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, with international search report (Art. 21(3)) TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
SG11201806127XA 2016-01-19 2017-01-16 Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate SG11201806127XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1600990.4A GB201600990D0 (en) 2016-01-19 2016-01-19 Pharmaceutical or nutritional combination
PCT/US2017/013672 WO2017127333A1 (en) 2016-01-19 2017-01-16 Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate

Publications (1)

Publication Number Publication Date
SG11201806127XA true SG11201806127XA (en) 2018-08-30

Family

ID=55488189

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806127XA SG11201806127XA (en) 2016-01-19 2017-01-16 Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate

Country Status (9)

Country Link
US (1) US20210220301A1 (en)
EP (1) EP3405186A1 (en)
JP (1) JP2019501980A (en)
CN (1) CN108495624A (en)
CA (1) CA3011633A1 (en)
GB (1) GB201600990D0 (en)
MX (1) MX2018008793A (en)
SG (1) SG11201806127XA (en)
WO (1) WO2017127333A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (en) 2016-12-19 2019-06-18 Axcella Health Inc Amino acid compositions and methods for the treatment of liver diseases
JP7266581B2 (en) 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド Amino acid composition for treatment of liver disease
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
WO2020064821A1 (en) * 2018-09-25 2020-04-02 Roquette Freres Food composition containing a mixture of leguminous proteins and casein
JP2020195286A (en) * 2019-05-31 2020-12-10 株式会社東洋新薬 Oral composition
JP2021070643A (en) * 2019-10-30 2021-05-06 小林製薬株式会社 Compositions for improving muscle mass
US11872197B2 (en) * 2020-03-03 2024-01-16 Another Chance Nutra, LLC Method of treatment or alleviating symptoms of a disorder with curcumin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064720A1 (en) * 2009-09-16 2011-03-17 Daniel Moses Amato Dietary Supplement Compositions and Methods of Making and Using the Same
EP2658535A1 (en) 2010-12-27 2013-11-06 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097061A1 (en) 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism
EP2580967A1 (en) * 2011-10-11 2013-04-17 Nestec S.A. Accelerating muscle recovery after immobilization-induced muscle atrophy
WO2014028607A1 (en) * 2012-08-14 2014-02-20 Abbott Laboratories Low glycemic index nutritional compositions for preserving muscle mass and improving body composition in diabetics

Also Published As

Publication number Publication date
CA3011633A1 (en) 2017-07-27
WO2017127333A1 (en) 2017-07-27
MX2018008793A (en) 2018-11-09
CN108495624A (en) 2018-09-04
US20210220301A1 (en) 2021-07-22
EP3405186A1 (en) 2018-11-28
JP2019501980A (en) 2019-01-24
GB201600990D0 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201906431UA (en) Method for the treatment of thromboembolism
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908367TA (en) Flavor modifiers for meat analog products
SG11201807912SA (en) Vaccine against rsv
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201907583TA (en) Methods for treating complement-mediated diseases and disorders
SG11201900975XA (en) Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201906853QA (en) Anti-rsv monoclonal antibody formulation
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201804770QA (en) Method and arrangement for recovery of salt
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808525UA (en) Anti-complement factor bb antibodies and uses thereof
SG11201804721SA (en) Modulators of complement activity
SG11201810801QA (en) Brain delivery protein
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201901347UA (en) Compositions and methods for cancer immunotherapy
SG11201805771XA (en) Systems and methods for preparation of platelets